本文首先对超声造影剂（UCA）的定义、发展、结构特点以及临床应用现状等进行概述，重点介绍了UCA在超声诊断和超声治疗方面的应用现状，然后探讨了UCA安全性问题，最后介绍了纳米级UCA等最新研究进展。本文对全面了解UCA特性、应用及安全性问题具有重要参考价值。

［1］Gramiak R，Shah P.Echocardiography of the aortic root ［J］.Investigative Radiology，1968，3:356-366.
［2］Hughes MS，Lanza GM，Marsh JN,et al.Targeted ultrasonic contrast agents for molecular imaging and therapy:a brief review［J］.MEDICA，2003，47:66-73.
［3］Schneider M.Molecular imaging and ultrasound-assisted drug delivery［J］.Journal of Endourology，2008，22(4):795-802.
［4］Armstrong WF，Ryan T.Stress echocardiography from 1979 to present ［J］.Journal of the American Society of Echocardiography，2008，21:22–28.
［5］Kaneko Y，Maruyama T，Takegami K，et al.Use of a microbubble agent to  increase the effects of high intensity focused ultrasound on liver tissue［J］.European Radiology，2005，15:1415–1420.
［6］Quaia E，Palumbo A，Rossi S,et al.Characterization of liver tumors insonated at low transmit power after microbubble contrast agent injection:comparison of visual and quantitative analysis in diagnostic performance［J］.AJR Am J Roentgenol，2006，186:1560–1570.
［7］Piscaglia F，Corradi F，Mancini M,et al.Real time contrast enhanced ultrasonography (CEUS) in detection of liver metastases from gastrointestinal cancer［J］.BMC Cancer，2007，7:171–184.
［8］Quaia ED，Onofrio M，Palumbo A，et al.Comparison of contrast-enhanced Ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver:diagnostic performance and confidence［J］.European Radiology，2006，16:1599–1609.
［9］Wilson SR，Burns PN.An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse inversion sonography ［J］.AJR Am J Roentgenol，2006，86:1401–1412.
［10］David Cosgrove，Chris Harvey.Clinical uses of microbubbles in diagnosis and treatment ［J］.Med Biol Eng Comput，2009，47:813–826.
［11］Behm C，Lindner J.Cellular and molecular imaging with targeted contrast ultrasound［J］.Ultrasound Quarterly，2006，22(1):67–72.
［12］华兴，高云华.超声波与声学造影剂在溶栓中的作用［J］.临床超声医学杂志，2006，(7):425-427.
［13］Alonso A，Della Martina A，Stroick M,et al.Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound［J］ .Stroke，2007，38:1508–1514.
［14］陈松.纳米液态氟碳微球超声造影剂的制备及体外寻靶实验研究［D］.重庆：重庆医科大学，2008.
［15］Yanagisawa K，Moriyasu F，Miyahara T，et al.Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells［J］.Ultrasound Med Biol，2007，33:318–325.
［16］Gail ter Haar.Safety and bio-effects of ultrasound contrast agent［J］.Medical and Biological Engineering and Computing，2009，47:893–900.
［17］Miller DL，Averkiou MA，Brayman AA,et al.Bioeffects considerations for diagnostic ultrasound contrast agents［J］.J Ultrasound Med，2008，27:611–632.
［18］Barnett SB，Duck F，Ziskin M.WFUMB symposium on safety of ultrasound in medicine:conclusions and recommendations on biological effects and safety of ultrasound contrast agents，2006［J］.Ultrasound Med Biol，2007，33:233–234.
［19］Main ML，Goldman JH，Grayburn PA.Thinking outside the “box”-the ultrasound contrast controversy［J］.Journal of the American College of Cardiology，2007，50:2434–2437.
［20］Kusnetzky L，Khalid A，Khumri T,et al.Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent:results in 18，671 consecutive studies［J］.Journal of the American College of Cardiology，2008，51:1704–1706.
［21］Duck F.Hazards，risks and safety of diagnostic ultrasound［J］.Med Eng Phys，2008，30:1338–1348.
［22］Dijkmans P，Visser C，Kamp O.Adverse reactions to ultrasound contrast agents:is the risk worth the benefit? ［J］.European Journal of Echocardiography，2005，6(5):363–366.
［23］Claudon M，Cosgrove D，Albrecht T,et al.Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)—update 2008［J］.Ultraschall Med，2008，29:28–44.